Antibe Therapeutics Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Antibe Therapeutics Inc. (ATBPF) is a clinical-stage biotechnology company that develops novel therapeutics and medical devices targeting pain, inflammation, and regenerative medicine through its proprietary hydrogen sulfide-releasing platform technology. The company offers otenaproxesul (formerly ATB-346), a hydrogen sulfide-releasing derivative of naproxen designed as a safer non-opioid analgesic for acute post-operative pain, migraines, dysmenorrhea, and dental pain without causing gastrointestinal damage; ATB-352, a candidate for specialized acute pain indications including gout and post-surgical pain; ATB-340, a preclinical asset for stroke and cancer; and through its subsidiary Citagenix Inc., a range of regenerative medicine products such as bone graft substitutes (C-Graft Putty, C-Blast Putty), barrier membranes (Eclipse, NeoGuarde, Neomem, Neomem FlexPlus), and orthobiologics (PentOS OI, Raptos) for dental and orthopedic markets. Founded in 2009 and headquartered at 15 Prince Arthur Avenue in Toronto, Ontario, Canada, Antibe Therapeutics previously operated in Canada, the United States, Europe, and internationally via direct sales and distributors. In January 2025, Taro Pharmaceuticals, a subsidiary of Sun Pharmaceutical Industries Ltd., entered into an agreement to acquire 100% of Antibe Therapeutics for CAD 4.5 million, subject to court approval and a reverse vesting order, with completion expected before March 7, 2025; this followed the company's bankruptcy in May 2024, delisting from the Toronto Stock Exchange, and placement under a court-appointed receiver. Earlier developments included a 2021 licensing deal with Nuance Pharma for up to $100 million in funding (with $20 million upfront) for otenaproxesul in Greater China, the 2015 acquisition of Citagenix, positive Phase 2 trial results for otenaproxesul in 2020, and plans for an upgraded Phase 2 abdominoplasty trial in early 2024 featuring placebo control, adaptive design, and enhanced sample size.
Analyzing Evelo Biosciences (NASDAQ:EVLO) & Antibe Therapeutics (OTCMKTS:ATBPD)
Antibe Announces Appointment of Receiver
Antibe Provides Update on CCAA Proceedings
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act
Antibe to Present Otenaproxesul PK/PD Results at the American Academy of Pain Medicine Meeting
Antibe Announces Unfavorable Decision in Arbitration With Nuance Pharma
Antibe Reports Q3 2024 Interim Financial and Operating Results
Antibe Extends Early Warrant Exercise Incentive Program
Antibe Announces Early Warrant Exercise Incentive Program
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Reports Q2 2024 Interim Financial and Operating Results
Antibe Reports PK Results of First Clinical Study of Otenaproxesul's New Formulation
Antibe Completes First Clinical Study of Otenaproxesul's New Formulation
Antibe Initiates First Clinical Study of Otenaproxesul's New Formulation
Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
Antibe Announces Results of 2023 Annual Meeting
Toronto Stock Exchange, Antibe Therapeutics Inc., View From The C-Suite
Antibe Reports Q1 2024 Interim Financial and Operating Results
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022